All In Biotech

Drug Trial Radar · NCT04934475

MInimal Residual Disease Adapted Strategy

MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study

Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 791 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

791

Actual

Start

Dec 8, 2021

Primary completion

Sep 30, 2024

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Intergroupe Francophone du MyelomeResearch network
Sponsor type
Research network
Collaborators
Amgen; Sanofi; Bristol-Myers Squibb
First posted
Jun 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 66 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).

Conditions

  • Multiple Myeloma

Interventions

  • IsatuximabDrug

    Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase

  • ASCTProcedure

    ASCT for ams B, C and D during consolidation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Negative MRD rateTime frame: Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months)
  2. Negative MRD rateTime frame: change from post induction baseline MRD at 1 years
  3. Negative MRD rateTime frame: change from post induction baseline MRD at 2 years
  4. Negative MRD rateTime frame: change from post induction baseline MRD at 3 years

Locations

73 sites in 3 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Grand Hôpital de Charleroi - Site de Notre-Dame

    Charleroi, Belgium

  • Hôpital Jolimont

    Haine-Saint-Paul, Belgium

  • CHU de Liège

    Liège, Belgium

  • CHU UCL Namur (Site Godinne)

    Yvoir, Belgium

  • CHU Amiens Sud

    Amiens, France

  • CHRU-Hôpital du Bocage

    Angers, France

  • Centre Hospitalier d'Argenteuil Victor Dupouy

    Argenteuil, France

  • Centre Hospitalier H.Duffaut

    Avignon, France

  • Centre hospitalier de la Côte Basque

    Bayonne, France

  • Hôpital Jean Minjoz

    Besançon, France

  • Centre Hospitalier Simone Veil

    Blois, France

  • Hôpital Avicenne

    Bobigny, France

  • Polyclinique Bordeaux Nord Acquitaine

    Bordeaux, France

  • CHRU Hôpital Haut Lévêque - Centre François Magendie

    Bordeaux Pessac, France

  • Hôpital de Fleyriat

    Bourg-en-Bresse, France

  • CHRU Brest - Hôpital A. Morvan

    Brest, France

  • CHU Caen - Côte de Nacre

    Caen, France

  • CH René Dubos

    Cergy-Pontoise, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, France

  • CH Chambéry

    Chambéry, France

  • Hôpital d'Instruction des Armées Percy

    Clamart, France

  • Chu Estaing

    Clermont-Ferrand, France

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France

  • CHU Henri Mondor

    Créteil, France

  • CHU Dijon Hôpital d'enfants

    Dijon, France

  • Centre Hospitalier Général

    Dunkirk, France

  • CHRU Hôpital A. Michallon

    Grenoble, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHV André Mignot - Université de Versailles

    Le Chesnay, France

  • CH de Chartres - Hôpital Louis Pasteur

    Le Coudray, France

  • Hôpital Jacques Monod

    Le Havre, France

  • Centre Hospitalier

    Le Mans, France

  • CHRU Hôpital Claude Huriez

    Lille, France

  • GH de l'Institut Catholique Saint Vincent

    Lille, France

  • Centre Hospitalier Universitaire (CHU) de Limoges

    Limoges, France

  • Hôpital du Scorff

    Lorient, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.